Diagnostic Accuracy and Outcome of Assessment Pathways for Women Recalled after Breast Cancer Screening
DOI:
https://doi.org/10.14738/bjhr.1304.1268Abstract
Introduction: Breast cancer is the most commonly diagnosed cancer among women globally, with an estimated 2.26 million new cases in 2020. The risk factors of breast cancer include age, genetic mutation and family history, racial and ethnic disparities, Increase in breast tissue density, etc. Early detection through organized screening programs plays a crucial role in improving survival by identifying cancer at stages when treatment is more likely to be curative. However, screening and diagnostic results can sometimes be misinterpreted, leading to false positives, false negatives, unnecessary follow-up tests, or over-diagnosis. Although digital mammography remains the standard, additional imaging methods are now used for high-risk individuals and those with dense breast tissue. Aims and Objectives: To evaluate the diagnostic accuracy, and the clinical, psychological, and diagnostic outcomes following recall after routine breast screening. The studies include a Cohort studies, Observational and Case-Control studies, Diagnostic accuracy and Screening Programs evaluations. Participants includes women aged 40 and older undergoing routing breast screening and were called back for additional assessment. Studies were conducted in several countries including Norway, Spain, etc. Ethical approval was not required for the studies as the participants clinical information was anonymized across all selected studies. Methodology: Data were collected using a computerized search strategy as the principle source of information from European Journal of Public Health, Journal of Breast Imaging, PubMed, etc. Results: Findings from the Randomized and Population-based Cohort study suggested that the screen-detected breast cancers indicated over-diagnosis rate of 14-39% with limited quality evidence. Data from the Observational studies estimated the 10-years cumulative probability of false-positive results with Film and Digital Mammography of 49% with limited quality evidence. Findings from the Cohorts studies showed that those women called back for further evaluation reported higher levels of anxiety, distress and pains with a moderate quality evidence. The harm of radiation exposure from mammography screening is based on only three modeling studies with moderate quality evidence.
References
American College of Radiology. (2016). ACR practice parameter for the performance of magnetic resonance imaging-guided breast interventional procedures.
BCSC, (2017). Screening Mammography Sensitivity, Specificity, & False Negative Rate. Breast Cancer Surveillance Consortium (BCSC) 2017. http://bcsc-research.org/(accessed August 21,2020).
Berg WA. (2016). Nuclear breast imaging: clinical results and future directions. J Nucl Med 2016; 57 Suppl 1:46S-52S. Doi: 10.2967/jnumed.115.157891.
Baltzer PAT, Kapetas P, et al. (2017). New diagnostic tools for breast cancer. Memo 2017; 10:175-80. Doi.10.1007/s12254-017-0341-5.
Barlow, W.E., Chi, C., Carney A., Taplin, S.H., D’Orsi, C., Cuttler, P. A., Taplin, S.H., D’Orsi, C., Cutter, G., Hendrick, R.E., & Elmore, J. G. (2004). Accuracy of screening mammography interpretation by characteristics of radiologists. JNCI Journal of the National Cancer Institute, 86(24),1840-1850.
Bickel H, Pinker-Domenig K. et al. (2015). Quantitative apparent diffusion coefficient as a noninvasive imaging biomarker for the differentiation of invasive breast cancer and ductal carcinoma in situ. Invest Radiol. 50:95-100.
Conti A. Duggento A. et al. (2020). Radiomics in breast cancer classification and prediction. Semin Cancer Biol; Doi: 10.1016/j.semcancer.04.002.
Coldman, A.J., Major, D., Doyle, G.P., D’yachkova, Y., Philips, N., Onysko, J., Shumak, R., Smith, N.E., & Wadden, N. (2006). Organized in breast screening programs in Canada: Effect of radiologist reading volumes on outcomes. Radiology, 238(3), 809-815.
Chetlen A, Mack J, Chan T. Breast cancer screeningcontroversies; who, when, why, and how? Clin Imaging 2016; 40:279-82. Doi: 10.1016/j. clinimag; 05.017.
Chilla GS, Tan CH, Xu C, Poh CL. (2015). Diffusion weighted magnetic resonance imaging and its recent trend-a survey. Quant Imaging Med Surg; 5:407-22. Doi: 10.3978/j.issn.2223-4292.03.1.
Cardoso F, Kyriakides S. et al. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnostic, treatment and follow-up. Ann Oncol 2019; 30:1194-220. Doi: 10.7326/M19-2125.
Crivelli P, Ledda RE, Parascandolo N, Fara A, Soro D, Conti M. (2018). A new challenge for radiologists:radiomics in breast cancer. Biomed Res Int. 6120703. Doi: 10.1155/2018/6120703.
Dai X, Xiang L, Li T, Bai Z. (2016). Cancer hallmarks, biomarkers and breast cancer molecular subtypes. J Cancer; 7:1281-94. Doi: 10.7150/jca.13141.
Scholar Publishing Dye, T.D., Bogale, S., Hobden, C., Tilahun, Y., Deressa, T., & Reeler, A. (2012). Experience of Initial Symptoms of Breast Cancer and Triggers for Action in Ethiopia. International Journal of Breast Cancer, 2012,1-5.
Elmore JG, Longton GM. Et al. (2015). Diagnostic concordance among pathologists interpreting breast biopsy specimens. JAMA 2015; 313:1122-32. Doi: 10. 1001/jama. 1405.
Gou C, Zhang C, Liu J, Tong L, Huang G. (2016). Is Tc-99m sestamibi sciintimammography useful in the prediction of neoadjuvant chemotherapy responses in breast cancer? A systematic review and meta-analysis. Nucl Med Commun 2016; 37:675-88.
Gilbert FJ, Tucker L, Young KC. (2016). Digital breast tomosynthesis (DBT): a review of the evidence for use as a screening tool. Clin Radiol 2016;71:141-50.
Gillies R, Kinahan PE, Hricak H. (2016). Radiomics: Images are more than pictures, they are Data. Radiology. 278:563-77. Doi: 10.1148/radio.2015151169.
Grandishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, et al. (2020). Breast Cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natle Compr Canc Netw; 18:452-78. Doi: 10.6004/jnccn.2020.0016.
Greene LR & Wilkinson D. (2015). The role of general nuclear medicine in breast cancer. J Med Radiat Sci, 62:54-65. Doi: 10.1002/jmrs.97.
Geisel J, Raghu M, Hooley R. (2017). The role of ultrasound in breast in breast cancer screening: the case for and against ultrasound. Semin Ultrasound CT MR ; 39:25-34.
Helvie MA. (2010). Digital Mammography imaging: breast tomosythesis and advanced applications. Radiol Clin North Am 2010;48:917-29. Doi: 10.1016/j.rcl.2010.06.009.
Iezzoni LI, Kilbridge K, Park ER. (2010). Physical access barriers to care for diagnosis and treatment of breast cancer among women with mobility impairments. Oncol Nurs Forum 2010;37:711-7. Doi: 10.1188/10.ONF. 711-717. Stic radiation force impulse imaging in benign and malignant breast lesions. Cureus; 9:el301.
Jayaraman J, Indiran V, Kannan K, Maduraimuthu P. (2017). AcouStic radiation force impulse imaging in benign and malignant breast lesions. Cureus; 9:el301.
Kontos M, Wilson R, Fentiman I. (2011). Digital Infrared thermal imaging (DITI) of breast lesions: sensitivity and specificity of detection of primary breast cancers. Clin Radiol 2011; 66:536-9. Doi:10.1016/j.crad.2011.01.009.
Lucznska E. (2017). Comparison of degree of enhancement on Contrast-Enhanced Spectral Mammography and Lesion characteristics on Mammography based on lesion histology. European Congress on Radiology 2017. Doi:10.1594/ecr2017/c-0831.
Liu G.Y, Lu J.S. et al. (2008). Fiberoptic ductoscopy combined with cytology testing in the patients of spontaneous nipple discharge. Breast Cancer Res Treat 2008; 108:271-7. Doi:10.1007/s10549-007-9598-4.
Mettler FA, Huda W, Yoshizumi TT, Mahesh M. (2008). Effective doses in radiology and diagnostic nuclear medicine: Radiology; 248:254-63.
Miglioretti, D. L., et al. (2015). Do mammographic technologists affect radiologists’ diagnostic mammography interpretative performance? American Journal of Roentgenology.
Miglioretti, D.L., Gard, C.C., Carney, P.A.,Onega, T.L., Buist, D.S.M., Sickles, E.A., Kerlikowske, K., Rosenberg, R.D., Yankaskas, B.C., Geller, B.M., & Elmore, J.G. (2009). When radiologists perform best: The learning curve in screening mammogram interpretation. Radiology, 253(3), 632-Scholar Publishing Miglioretti, D.L., Smith-Bindman, R., Abrham, L., Brenner, R.J., Carney, P.A., Bowles, E.J.A.,
Buist, D.S.M., & Elmore, J.G. (2007). Radiologist characteristics associated with interpretive performance of diagnostic mammography. JNCI: Journal of the National Cancer Institute, 99(24), 1854-1863.
Mankoff D.A, Gralow RR. (2007). The Role of FDG-PET/CT in Suspected Recurrence of Breast Cancer. Breast Disease: A Year Book Quarterl 2007; 18:251-2.
Mann RM, Balleyguier C, Baltzer PA, Bick U, Colin C, Cornford E. et al. (2015). Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol; 25:3669-78. Doi: 10.1007/s00330-015-3807-z.
Mazzocco K, Masiero M, Carriro MC, Pravettoni G. (2019). The role of emotions in cancer patients’ decision-making. Ecancermedicalscience 2019;13-914. Doi.10.3332/ecancer.2019.914.
Rahbar H, Lee JM, Lee CI. (2020). Optimal screening in breast cancer survivors with dense breasts on mammography. J Clin Oncol 2020: JCO2001641. Doi: 10.1200/JCO.20.01641.
Oeffinger KC, Fontham ETH, Etzioni R, Herzig A, Michaelson JS, Shih Y-CT, et al. (2015). Breast Cancer Screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA 314:1599-614. Doi: 10.1001/jama. 2015.12783.
Poiseuil M, Coureau G. et al. (2019). Deprivation and mass screening: Survival of women diagnosed with breast cancer in France from 2008 to 2010. Cancer Epidemiol 2019; 60:149-55. Doi: 10.1016/j.canep. 2019.03.016.
Partridge SC, Nisaan N, Rahbar H, Kitsch AE, Sigmund EE. (2017). Diffusion-weighted breast MRI: Clinical applications and emerging techniques. J Magn Reson Imaging. 45:337-55. Doi: 10.1002/jmri.25479.
Siu AL, U.S. (2016). Preventive Services Task Force. Screening for breast cancer: U.S Preventive Services task force recommendation statement. Ann Interm Med ; 164-279-96. Doi: 7326/M15-2886.
Smetherman DH. (2013). Screening, imaging, and image-guided biopsy techniques for breast cancer. Surge Clin North Am 2013; 93:309-27. Doi:10.1016/j.suc.2013.01.004. 003.
Schelfout K, Van Goethem M, Kersschot E, Colpaert C, Schelfhout AM, Leyman P, et al.(2004). Contrast-enhanced MR imaging of breast lesions and effect on treatment. Eur J Surg Oncol; 30:501-7. Doi: 10.1016/j.eso.2004.02.
Semenza GL. (2015). The hypoxic tumor microenvironment: A driving force for breast cancer progression. Biochim Biophys Acta 2016; 1863:382-91. Doi: 10.1016/j.bbamcr. 2015.05.036.
Tran WT, Jeezak. Et al. (2019). Personalized breast cancer treatments using artificial intelligent in radiomics and pathomics. J Med Imaging Radiat Sci; 50:S32-41. Doi: 10.1016/jmi.2019.07.010.
Qaseem A, Snow V, Sherif K, Aronson M, Weiss KB, Owens DK. Et al. (2007). Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Ann Intem Med 2007;146:511-5.
Valdora F, Houssami N, Rossi F, Calabrese M, Tagliafico AS. (2018). Rapid review: Radiomics and breast cancer. Breast Cancer Res Treat 2018;169:217-29. Doi: 10.1007/s10549-018-4675-4.
Welch HG, Prorok PC. et al. (2016). Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. N Engl J Med 2016; 375;1438-47. Doi: 10.1056/NEJMoa1600249.
Wong, D,J., Gandomkar, Z., Lewis, S., Reed, W., Suleiman, M., Siviengphanom, S., & E. (2023). Do reader characteristics affect diagnostic efficiency in screening review. Clinical Breast Cancer, 23, e56-e67.
Waks, A.G., & Winer, E. P. (2019). Breast Cancer Treatment. JAMA, 321(3),288-300. Scholar Publishing
Yuan. (2026). Chinese expert consensus on endocrine therapy for breast cancer (2026) edition). Translational Breast Cancer Research.
Zhang Q, Xia Y, Suo J, Shi J, Yu J, Guo Y, et al. (2016). Sonoelastomics for Breast Tumor Classification: A Radiomics Approach with Clustering-Based Features Selection on Sonoelastography. Ultrasound Med Biol; 43:1058-69. Doi: 10.1016/j.ultrasmedbio.2016.12.016.
U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151:716-26. [PMID: 19920272] doi:10.7326/0003-4819-151-10-200911170-00008.
Siegel RL, Miller KD, Fuchs HE, et al . (2022). Cancer statistics, 2022. CA Cancer J Clin 2022;72:7–33. doi:10.3322/caac.21708 Cross Ref PubMedGoogle Scholar.
Miglioretti DL, Gard CC, Carney PA, et al.(2009). When radiologists perform best: the learning curve in screening mammogram nterpretation. Radiology 2009;253:632–40. doi:10.1148/radiol.2533090070CrossRefPubMedGoogle Scholar.
Uzun Ozsahin D, Ikechukwu Emegano D, Uzun B, et al . (2022).The Systematic Review of Artificial Intelligence Applications in Breast Cancer Diagnosis. Diagnostics (Basel) 2022;13:45. doi:10.3390/diagnostics13010045 Google Scholar.
Wong DJ, Gandomkar Z, Wu W-J, et al . (2020). Artificial intelligence and convolution neural networks assessing mammographic images: a narrative literature review. J Med Radiat Sci 2020;67:134– doi:10.1002/jmrs.385 PubMed Google Scholar.
Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Piñeros M., Znaor A., Soerjomataram I., Bray F. (2021). Global Cancer Obser-Vatory: Cancer Today. International Agency for Research on Cancer; Lyon, France: 2020. [(accessed on 9 July 2021)]. Available online: https://gco.iarc.fr/today. Google Scholar.
DeSantis C.E., Fedewa S.A., Sauer A.G., Kramer J.L., Smith R.A., Jemal A.(2015). Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA A Cancer J.
Clin. 2015;66:31–42. doi: 10.3322/caac.21320. [DOI] [PubMed] [Google Scholar.
Sharma R. (2019). Breast cancer incidence, mortality and mortality-to-incidence ratio (MIR) are associated with human development, 1990–2016: Evidence from Global Burden of Disease Study 2016. Breast Cancer. 2019;26:428–445. doi: 10.1007/s12282-018-00941-4. [DOI] [PubMed] [Google Vostakolaei F.A., Karim-Kos H.E., Janssen-Heijnen M.L.G., Visser O., Verbeek A.L.M., Kiemeney L. (2010). The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival.
Eur. J. Public Health. 2010;21:573–577. doi: 10.1093/eurpub/ckq120. [DOI] [PubMed] [Google Sankaranarayanan R., Swaminathan R., Brenner H., Chen K., Chia K.S., Chen J.-G., Law S.C., Ahn
Y.-O., Xiang Y.B., Yeole B.B., et al. (2010). Cancer survival in Africa, Asia, and Central America: A population-based study. Lancet Oncol. 2010;11:165–173. doi: 10.1016/S1470-2045(09)70335-[DOI] [PubMed] [Google Scholar.
Ferlay J., Laversanne M., Ervik M., Lam F., Colombet M., Mery L., Piñeros M., Znaor A., Soerjomataram I., Bray F. (2020).International Agency for Research on Cancer; Lyon, France: 2020. [(accessed on 9 July 2021)]. Global Cancer Observatory: Cancer Tomorrow. Available online: https://gco.iarc.fr/tomorrow. [Google Scholar.
Porter P. (2008). Westernizing Women’s Risks? Breast Cancer in Lower-Income Countries. N. Engl. J.
Med. 2008;358:213–216. doi: 10.1056/NEJMp0708307. [DOI] [PubMed] [Google Scholar. Scholar Publishing Weigelt B., Horlings H.M., Kreike B., Hayes M.M., Hauptmann M., Wessels L.F.A., De Jong D., van
de Vijver M., Veer L.J.V., Peterse J.L. (2008). Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 2008;216:141–150. doi: 10.1002/path.2407. [DOI] [PubMed] [Google Scholar].
Tavassoli F.A. (2020). Pathology and Genetics of Tumours of the Breast and Female Genital Organs. World Hhealth Organization Classification of Tumours; Lyon, France: 2003. [Google Scholar].
Erber R., Hartmann A. (2020). Histology of Luminal Breast Cancer. Breast Care. 2020;15:327–336. doi: 10.1159/000509025. [DOI] [PMC free article] [PubMed] [Google Scholar].
Howlader N., Altekruse S.F., Li C.I., Chen V.W., Clarke C.A., Ries L.A.G., Cronin K.A. (2014). US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. J. Natl.
Cancer Inst. 2014;106:dju055. doi: 10.1093/jnci/dju055. [DOI] [PMC free article] [PubMed] [Google
Weigelt B., Geyer F.C., Reis-Filho J.S. (2010). Histological types of breast cancer: How special are they? Mol. Oncol. 2010;4:192–208. doi: 10.1016/j.molonc.2010.04.004. [DOI] [PMC free article]
Makki J. (2015). Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. Clin.
Med. Insights Pathol. 2015;8:23–31. doi: 10.4137/CPath.S31563. [DOI] [PMC free article] [PubMed]
Ades F. (2014). Luminal B breast cancer: Molecular characterization, clinical management, and future perspectives. J. Clin. Oncol. 2014;32:2794–2803. doi: 10.1200/JCO.2013.54.1870. [DOI]
Cheang M.C.U., Chia S.K., Voduc D., Gao D., Leung S., Snider J., Watson M., Davies S., Bernard P.S., Parker J.S., et al.(2009). Ki67 Index, HER2 Status, and Prognosis of Patients with Luminal B Breast Cancer. J. Natl. Cancer Inst. 2009;101:736–750. doi: 10.1093/jnci/djp082. [DOI] [PMC free article] [PubMed] [Google Scholar
Raj-Kumar P.-K., Liu J., Hooke J.A., Kovatich A.J., Kvecher L., Shriver C.D., Hu H. (2019). PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B. Sci. Rep. 2019;9:7956. doi: 10.1038/s41598-019-44339-4. [DOI] [PMC free article] [PubMed] [Google Scholar].
Ranjit K. Breast cancer. Lancet. 2005;365:1742. doi: 10.1016/S0140-6736(05)66547-6. [DOI]
Roberts S.A., Lawrence M.S., Klimczak L.J., Grimm S.A., Fargo D., Stojanov P., Kiezun A., Kryukov G., Carter S.L., Saksena G., et al. (2013). An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 2013; 45:970–976. doi: 10.1038/ng.2702. [DOI] [PMC free article] [PubMed] [Google Scholar].
Plasilova M.L., Hayse B., Killelea B.K., Horowitz N.R., Chagpar A.B., Lannin D.R. (2016). Features of triple-negative breast cancer. Medicine. 2016;95:e4614. doi: 10.1097/MD.0000000000004614. [DOI] [PMC free article] [PubMed] [Google Scholar].
Newman L.A., Reis-Filho J.S., Morrow M., Carey L.A., King T.A. (2014).The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer. Ann. Surg.
Oncol. 2014;22:874–882. doi: 10.1245/s10434-014-4279-0. [DOI] [PubMed] [Google Scholar].
Pareja F. (2016). Triple-negative breast cancer: The importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer. 2016;2:16036. doi: 10.1038/npjbcancer.2016.36. [DOI] [PMC free article] [PubMed] [Google Scholar]. Scholar Publishing
Wetterskog D. (2012). Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J. Pathol. 2012;226:84–96. doi: 10.1002/path.2974. [DOI] [PubMed] [Google Scholar].
Badve S., Dabbs D.J., Schnitt S.J., Baehner F.L., Decker T., Eusebi V., Fox S., Ichihara S., Jacquemier J., Lakhani S.R., et al. (2010). Basal-like and triple-negative breast cancers: A critical review with an emphasis on the implications for pathologists and oncologists. Mod. Pathol. 2010;24:157–167. doi: 10.1038/modpathol.2010.200. [DOI] [PubMed] [Google Scholar].
Weiss A., Mac Gregor M.C., Lichtensztajn D., Yi M., Tadros A., Hortobagyi G.N., Giordano S.H., Hunt K.K., Mittendorf E.A. (2018). Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared with the Anatomic Stage in Breast Cancer. JAMA Oncol. 2018;4:203–209. doi: 10.1001/jamaoncol.2017.4298. [DOI] [PMC free article] [PubMed] [Google Stat Bite: Lifetime Probability among Females of Dying of Cancer. JNCI J. Natl. Cancer Inst. 2004;96:1311–1321. doi: 10.1093/jnci/96.11.818. [DOI] [PubMed] [Google Scholar].
Benz C.C.(2007). Impact of aging on the biology of breast cancer. Crit. Rev. Oncol. 2008;66:65–74. doi: 10.1016/j.critrevonc.2007.09.001. [DOI] [PMC free article] [PubMed] [Google Scholar].
McGuire A., Brown J.A.L., Malone C., McLaughlin R., Kerin M.J. (2015). Effects of Age on the Detection and Management of Breast Cancer. Cancers. 2015;7:908–929. doi: 10.3390/cancers7020815. [DOI] [PMC free article] [PubMed] [Google Scholar]. Collaborative Group on Hormonal Factors in Breast Cancer Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358:1389–1399. doi: 10.1016/S0140-6736(01)06524-2. [DOI] [PubMed] [Google Scholar].
Shiyanbola O.O., Arao R.F., Miglioretti D.L., Sprague B.L., Hampton J.M., Stout N.K., Kerlikowske K., Braithwaite D., Buist D.S., Egan K.M., et al.(2017). Emerging Trends in Family History of Breast Cancer and Associated Risk. Cancer Epidemiol. Biomark. Prev. 2017;26:1753–1760. doi: 10.1158/1055-9965.EPI-17-0531. [DOI] [PMC free article] [PubMed] [Google Scholar].
Baglia M.L., Tang M.-T.C., Malone K.E., Porter P., Li C.I. (2018). Family History and Risk of Second Primary Breast Cancer after In Situ Breast Carcinoma. Cancer Epidemiol. Biomark. Prev. 2018;27:315–320. doi: 10.1158/1055-9965.EPI-17-0837. [DOI] [PMC free article] [PubMed] [Google
Brewer H.R., Jones M.E., Schoemaker M.J., Ashworth A., Swerdlow A.J. (2017). Family history and risk of breast cancer: An analysis accounting for family structure. Breast Cancer Res. Treat. 2017;165:193–200. doi: 10.1007/s10549-017-4325-2. [DOI] [PMC free article] [PubMed] [Google
Shiovitz S., Korde L.A. (2015). Genetics of breast cancer: A topic in evolution. Ann. Oncol. 2015;26:1291–1299. doi: 10.1093/annonc/mdv022. [DOI] [PMC free article] [PubMed] [Google
Shahbandi A., Nguyen H.D., Jackson J.G.(2020). TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines. Trends Cancer. 2020;6:98–110. doi: 10.1016/j.trecan.2020.01.007. [DOI] [PMC free article] [PubMed] [Google Scholar].
Corso G., Veronesi P., Sacchini V., Galimberti V. (2018). Prognosis and outcome in CDH1-mutant lobular breast cancer. Eur. J. Cancer Prev. 2018;27:237–238. doi: 10.1097/CEJ.0000000000000405. [DOI] [PMC free article] [PubMed] [Google Scholar]. Scholar Publishing
Corso G., Intra M., Trentin C., Veronesi P., Galimberti V. (2016). CDH1 germline mutations and hereditary lobular breast cancer. Fam. Cancer. 2016;15:215–219. doi: 10.1007/s10689-016-9869-5. [DOI] [PubMed] [Google Scholar].
Kechagioglou P., Papi R.M., Provatopoulou X., Kalogera E., Papadimitriou E., Grigoropoulos P., Nonni A., Zografos G., Kyriakidis D.A., Gounaris A. (2014). Tumor suppressor PTEN in breast cancer: Heterozygosity, mutations and protein expression. Anticancer. Res. 2014;34:1387–1400. [PubMed]
Hill D.A., Prossnitz E.R., Royce M., Nibbe A. (2019). Temporal trends in breast cancer survival by race and ethnicity: A population-based cohort study. PLoS ONE. 2019;14:e0224064. doi: 10.1371/journal.pone.0224064. [DOI] [PMC free article] [PubMed] [Google Scholar].
Yedjou C.G., Sims J.N., Miele L., Noubissi F., Lowe L., Fonseca D.D., Alo R.A., Payton M., Tchounwou P.B. (2019). Health and Racial Disparity in Breast Cancer. Adv. Exp. Med. Biol. 2019;1152:31–49. doi: 10.1007/978-3-030-20301-6_3. [DOI] [PMC free article] [PubMed] [Google
American Cancer Society (2016) Breast Cancer Facts & Figures, 2015–2016. American Cancer Society; Atlanta, GA, USA: 2016. [Google Scholar].
Bernstein L. (2002). Epidemiology of Endocrine-Related Risk Factors for Breast Cancer. J. Mammary Gland. Biol. Neoplasia. 2002;7:3–15. doi: 10.1023/A:1015714305420. [DOI] [PubMed] [Google
Albrektsen G., Heuch I., Hansen S., Kvåle G. (2004). Breast cancer risk by age at birth, time since birth and time intervals between births: Exploring interaction effects. Br. J. Cancer. 2004;92:167–175. doi: 10.1038/sj.bjc.6602302. [DOI] [PMC free article] [PubMed] [Google Scholar].
Husby A., Wohlfahrt J., Øyen N., Melbye M. (2018). Pregnancy duration and breast cancer risk. Nat.
Commun. 2018;9:4255. doi: 10.1038/s41467-018-06748-3. [DOI] [PMC free article] [PubMed]
Checka C.M., Chun J.E., Schnabel F.R., Lee J., Toth H. (2012). The Relationship of Mammographic Density and Age: Implications for Breast Cancer Screening. Am. J. Roentgenol. 2012;198:W292–W295. doi: 10.2214/AJR.10.6049. [DOI] [PubMed] [Google Scholar].
Kim E.Y., Chang Y., Ahn J., Yun J., Park Y.L., Park C.H., Shin H., Ryu S. (2020). Mammographic breast density, its changes, and breast cancer risk in premenopausal and postmenopausal women.
Cancer. 2020;126:4687–4696. doi: 10.1002/cncr.33138. [DOI] [PubMed] [Google Scholar].
Duffy S.W., Morrish O.W., Allgood P.C., Black R., Gillan M.G., Willsher P., Cooke J., Duncan K.A., Michell M.J., Dobson H.M., et al. (2017). Mammographic density and breast cancer risk in breast screening assessment cases and women with a family history of breast cancer. Eur. J. Cancer. 2017;88:48–56. doi: 10.1016/j.ejca.2017.10.022. [DOI] [PMC free article] [PubMed] [Google
Chen X., Wang Q., Zhang Y., Xie Q., Tan X. (2018). Physical Activity and Risk of Breast Cancer: A Meta-Analysis of 38 Cohort Studies in 45 Study Reports. Value Health. 2018;22:104–128. doi: 10.1016/j.jval.2018.06.020. [DOI] [PubMed] [Google Scholar].
Kyu H.H., Bachman V.F., Alexander L.T., Mumford J.E., Afshin A., Estep K., Veerman L., Delwiche K., Iannarone M.L., Moyer M.L., et al. (2013). Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: Systematic review and doseresponse meta-analysis for the Global Burden of Disease Study 2013. BMJ. 2016;354:i3857. doi: 10.1136/bmj.i3857. [DOI] [PMC free article] [PubMed] [Google Scholar].
Scholar Publishing Hoffinan-Goetz L. (2009). Influence of Physical Activity and Exercise on Innate Immunity. Nutr. Rev. 2009;56:S126–S130. doi: 10.1111/j.1753-4887.1998.tb01629.x. [DOI] [PubMed] [Google Scholar][Ref list].
Wang X., Hui T.-L., Wang M.-Q., Liu H., Li R.-Y., Song Z.-C. (2019). Body Mass Index at Diagnosis as a Prognostic Factor for Early-Stage Invasive Breast Cancer after Surgical Resection. Oncol. Res.
Treat. 2019;42:195–201. doi: 10.1159/000496548. [DOI] [PubMed] [Google Scholar].
James F., Wootton S., Jackson A., Wiseman M., Copson E., Cutress R. (2015). Obesity in breast cancer—What is the risk factor? Eur. J. Cancer. 2015;51:705–720. doi: 10.1016/j.ejca.2015.01.057. [DOI] [PubMed] [Google Scholar].
Protani M., Coory M., Martin J. (2010). Effect of obesity on survival of women with breast cancer: Systematic review and meta-analysis. Breast Cancer Res. Treat. 2010;123:627–635. doi: 10.1007/s10549-010-0990-0. [DOI] [PubMed] [Google Scholar].
Rachdaoui N., Sarkar D.K.(2013). Effects of Alcohol on the Endocrine System. Endocrinol. Metab.
Clin. N. Am. 2013;42:593–615. doi: 10.1016/j.ecl.2013.05.008. [DOI] [PMC free article] [PubMed]
Erol A., Ho A.M.-C., Winham S.J., Karpyak V.M. (2017). Sex hormones in alcohol consumption: A systematic review of evidence. Addict. Biol. 2017;24:157–169. doi: 10.1111/adb.12589. [DOI] [PMC free article] [PubMed] [Google Scholar].
Terry P.D., Rohan T.E. (2002). Cigarette smoking and the risk of breast cancer in women: A review of the literature. Cancer Epidemiol. Biomark. Prev. 2002;11:953–971. [PubMed] [Google Scholar].
Catsburg C., Miller A.B., Rohan T.E. (2014). Active cigarette smoking and risk of breast cancer.
Int. J. Cancer. 2014;136:2204–2209. doi: 10.1002/ijc.29266. [DOI] [PubMed] [Google Scholar].
Jones M., Schoemaker M.J., Wright L.B., Ashworth A., Swerdlow A.J. (2017). Smoking and risk of breast cancer in the Generations Study cohort. Breast Cancer Res. 2017;19:118. doi: 10.1186/s13058-017-0908-4. [DOI] [PMC free article] [PubMed] [Google Scholar].
Misotti A.M., Gnagnarella P. (2013). Ecancermedicalscience. Ecancermedicalscience. 2013;7:365. doi: 10.3332/ecancer.2013.365. [DOI] [PMC free article] [PubMed] [Google Scholar].
Cui Y. (2006). Vitamin D, Calcium, and Breast Cancer Risk: A Review. Cancer Epidemiol. Biomark.
Prev. 2006;15:1427–1437. doi: 10.1158/1055-9965.EPI-06-0075. [DOI] [PubMed] [Google Scholar].
Atoum M., Alzoughool F. (2017). Vitamin D and Breast Cancer: Latest Evidence and Future Steps. Breast Cancer: Basic Clin. Res. 2017;11:1178223417749816. doi: 10.1177/1178223417749816. [DOI] [PMC free article] [PubMed] [Google Scholar].
El-Sharkawy A., Malki A. (2020). Vitamin D Signaling in Inflammation and Cancer: Molecular Mechanisms and Therapeutic Implications. Molecules. 2020;25:3219. doi: 10.3390/molecules25143219. [DOI] [PMC free article] [PubMed] [Google Scholar].
Estébanez N., Gómez-Acebo I., Palazuelos C., Llorca J., Dierssen-Sotos T. (2018). Vitamin D exposure and Risk of Breast Cancer: A meta-analysis. Sci. Rep. 2018;8:9039. doi: 10.1038/s41598-018-27297-1. [DOI] [PMC free article] [PubMed] [Google Scholar].
Huss L., Butt S.T., Borgquist S., Elebro K., Sandsveden M., Rosendahl A., Manjer J. (2019). Vitamin D receptor expression in invasive breast tumors and breast cancer survival. Breast Cancer Res. 2019;21:84. doi: 10.1186/s13058-019-1169-1. [DOI] [PMC free article] [PubMed] [Google Scholar].
Zhou L., Chen B., Sheng L., Turner A. (2020). The effect of vitamin D supplementation on the risk of breast cancer: A trial sequential meta-analysis. Breast Cancer Res. Treat. 2020;182:1–8. doi: 10.1007/s10549-020-05669-4. [DOI] [PubMed] [Google Scholar.
Scholar Publishing Al-Naggar R.A., Anil S. (2016). Artificial Light at Night and Cancer: Global Study. Asian Pac. J.
Cancer Prev. 2016;17:4661–4664. doi: 10.22034/APJCP.2016.17.10.4661. [DOI] [PMC free article]
Johns L.E., Jones M., Schoemaker M., McFadden E., Ashworth A., Swerdlow A. (2018). Domestic light at night and breast cancer risk: A prospective analysis of 105,000 UK women in the Generations Study. Br. J. Cancer. 2018;118:600–606. doi: 10.1038/bjc.2017.359. [DOI] [PMC free article] [PubMed] [Google Scholar].
Myers, E.R. ∙ Moorman, P. ∙ Gierisch, J.M. (2015). Benefits and harms of breast Cancer screening: a systematic review JAMA. 2015; 314:1615-1634 Crossref Scopus (465) PubMed Google Scholar.
Sankatsing, V.D.V. ∙ van Ravesteyn, N.T. ∙ Heijnsdijk, E.A.M. (2017). The effect of population-based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up Int. J. Cancer. 2017; 141:671-677 Crossref Scopus (55) PubMed Google Scholar.
World Health Organisation.(2002). International agency for research on cancer. breast cancer screening. WHO: International Agency for Research on Cancer, 2002.Google Scholar.
Brodersen J, Siersma VD. (2013). Long-Term psychosocial consequences of false-positive screening mammography. Ann Fam Med 2013;11:106–15. doi:10.1370/afm.1466 Abstract/FREE Full TextGoogle Scholar.
Elmore JG, Miglioretti DL, Reisch LM, et al. (2002). Screening mammograms by community radiologists: variability in false-positive rates. J Natl Cancer Inst 2002;94:1373–80. doi:10.1093/jnci/94.18.1373 CrossRefPubMedWeb of ScienceGoogle Scholar. Barratt A, Howard K, Irwig L, et al. Model of outcomes of screening mammography: information to support informed choices. BMJ 2005;330:936. doi:10.1136/bmj.38398.469479.8F Google Scholar.
Castells X, Molins E,Macià F.(2006). Cumulative false positive recall rate and association with participant related factors in a population based breast cancer screening programme. J Epidemiol Community Health 2006;60:316–21. doi:10.1136/jech.2005.042119 Abstract/FREE Full TextGoogle
Roman M, Hubbard RA, Sebuodegard S, et al. (2013). The cumulative risk of false-positive results in the Norwegian breast cancer screening program: updated results. Cancer 2013;119:3952–8. doi:10.1002/cncr.28320 CrossRefPubMedGoogle Scholar.
Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. (2011). Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med. 2011;155:481-92. [PMID: 22007042] doi:10.7326/0003-4819-155-8-201110180-00004.
Kerlikowske K, Zhu W, Hubbard RA, Geller B, Dittus K, Braithwaite D, et al. (2013). Breast Cancer Surveillance Consortium. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA Intern Med. 2013;173:807-16. [PMID: 23552817] doi:10.1001/jamainternmed.2013.307.
Christiansen CL, Wang F, Barton MB, et al. (2013). Predicting the cumulative risk of false-positive mammograms. J Natl Cancer Inst 92 (20): 1657-66, 2000. [PubMed].
Kerlikowske K, Zhu W, Hubbard RA, et al.: Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA Intern Med 173 (9): 807-16, 2013. [PMC free article] [PubMed].
Jørgensen KJ, Gøtzsche PC, Kalager M, et al. (2017). Breast Cancer Screening in Denmark: A Cohort Study of Tumor Size and Overdiagnosis. Ann Intern Med 166 (5): 313-323, 2017. [PubMed]. Scholar Publishing
Autier P, Boniol M, Koechlin A, et al. (2017). Effectiveness of and overdiagnosis from mammography screening in the Netherlands: population based study. BMJ 359: j5224, 2017. [PMC free article] [PubMed].
Harding C, Pompei F, Burmistrov D, et al. (2015). Breast Cancer Screening, Incidence, and Mortality Across US Counties. JAMA Intern Med 175 (9): 1483-9, 2015. [PubMed].
Miller AB, Wall C, Baines CJ, et al.: Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348: g366, 2014. [PMC free article] [PubMed].
Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. (2013). The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108:2205-40. [PMID: 23744281] doi:10.1038/bjc.2013.177.
Independent UK Panel on Breast Cancer Screening. (2012). The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380:1778-86. [PMID: 23117178] doi:10.1016/S0140-6736 (12)61611-0.
Miller AB, To T, Baines CJ, Wall C. (2002). The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med. 2002;137:305-12. [PMID: 12204013] doi:10.7326/0003-4819-137-5_Part_1-200209030-00005.
Puliti D, Duffy SW, Miccinesi G, de Koning H, Lynge E, Zappa M, et al. (2012). EUROSCREEN Working Group. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review.
J Med Screen. 2012;19 Suppl 1:42-56. [PMID: 22972810].
Brett J, Bankhead C, Henderson B, Watson E, Austoker J. (2005). The psychological impact of mammographic screening. A systematic review. Psychooncology. 2005;14:917-38. [PMID: 15786514]
Brewer NT, Salz T, Lillie SE. (2007). Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med. 2007;146: 502-10. [PMID: 17404352] doi:10.7326/0003-4819-146-7-200704030 -00006.
Hafslund B, Nortvedt MW. (2009). Mammography screening from the perspective of quality of life: a review of the literature. Scand J Caring Sci. 2009;23:539-48. [PMID: 19170959] doi:10.1111/j.1471-6712 .2008.00634.
Hislop TG, Harris SR, Jackson J, Thorne SE, Rousseau EJ, Coldman AJ, et al. (2002). Satisfaction and anxiety for women during investigation of an abnormal screening mammogram. Breast Cancer Res Treat. 2002;76:245-54. [PMID: 12462385].
Brett J, Austoker J. (2001). Women who are recalled for further investigation for breast screening: psychological consequences 3 years after recall and factors affecting re-attendance. J Public Health Med. 2001;23:292-300. [PMID: 11873891]
Bond M, Pavey T, Welch K, Cooper C, Garside R, Dean S, et al. (2013). Psychological consequences of false-positive screening mammograms in the UK. Evid Based Med. 2013;18:54-61. [PMID: 22859786] doi:10.1136/eb-2012-100608
Gibson CJ, Weiss J, Goodrich M, Onega T. (2009). False-positive mammography and depressed mood in a screening population: findings from the New Hampshire Mammography Network. J Public Health (Oxf). 2009;31:554-60. [PMID: 19574274] doi:10.1093/pubmed /fdp064
Keyzer-Dekker CM, De Vries J, van Esch L, Ernst MF, Nieuwenhuijzen GA, Roukema JA, et al. (2012).
Anxiety after an abnormal screening mammogram is a serious problem. Breast. 2012;21:83-8. [PMID: 21924905] doi:10.1016/j.breast.2011.08.137
Scholar Publishing Brodersen J, Siersma VD. (2013). Long-term psychosocial consequences of false-positive screening mammography. Ann Fam Med. 2013;11: 106-15. [PMID: 23508596] doi:10.1370/afm.1466
Tosteson AN, Fryback DG, Hammond CS, Hanna LG, Grove MR, Brown M, et al. (2014).
Consequences of false-positive screening mammograms. JAMA Intern Med. 2014;174:954-61. [PMID: 24756610] doi: 10.1001/jamainternmed.2014.981
Espasa R, Murta-Nascimento C, Baye´ s R, Sala M, Casamitjana M, Macia` F, et al. (2012). The psychological impact of a false-positive screening mammogram in Barcelona. J Cancer Educ. 2012;27:780-5. [PMID: 22477233] doi:10.1007/s13187-012-0349-9
Schou Bredal I, Kåresen R, Skaane P, Engelstad KS, Ekeberg Ø (2013). Recall mammography and psychological distress. Eur J Cancer. 2013;49:805-11. [PMID: 23021930] doi:10.1016/j.ejca.2012.09.001
Hafslund B, Espehaug B, Nortvedt MW. (2012). Effects of false-positive results in a breast screening program on anxiety, depression and health-related quality of life. Cancer Nurs. 2012;35:E26-34. [PMID: 22067696] doi:10.1097/NCC.0b013e3182341ddb
Fitzpatrick P, Fleming P, O’Neill S, Kiernan D, Mooney T. (2011). Falsepositive mammographic screening: factors influencing reattendance over a decade of screening. J Med Screen. 2011;18: 30-3. [PMID: 21536814] doi:10.1258/jms.2010.010104
Klompenhouwer EG, Duijm LE, Voogd AC, den Heeten GJ, Strobbe LJ, Louwman MW, et al. (2014). Re-attendance at biennial screening mammography following a repeated false positive recall.
Breast Cancer Res Treat. 2014;145:429-37. [PMID: 24748569] doi:10.1007 /s10549-014-2959-x
Maxwell AJ, Beattie C, Lavelle J, Lyburn I, Sinnatamby R, Garnett S, et al. (2013). The effect of false positive breast screening examinations on subsequent attendance: retrospective cohort study.
J Med Screen. 2013;20:91-8. [PMID: 24009091] doi:10.1177/0969141313499147.
Sandin B, Chorot P, Valiente RM, et al. (2002). Adverse psychological effects in women attending a second-stage breast cancer screening. J Psychosom Res 52 (5): 303-9, 2002. [PubMed].
Armstrong K, Moye E, Williams S, Berlin JA, Reynolds EE. (2007). Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. Ann Intern Med. 2007;146:516-26. [PMID: 17404354] doi:10.7326/0003-4819-146-7 -200704030-00008.
Whelehan P, Evans A, Wells M, Macgillivray S. (2013). The effect of mammography pain on repeat participation in breast cancer screening: a systematic review. Breast. 2013;22:389-94. [PMID: 23541681] doi:10.1016/j.breast.2013.03.003.
Miller D, Livingstone V, Herbison P. (2008). Interventions for relieving the pain and discomfort of screening mammography. Cochrane Database Syst Rev. 2008:CD002942. [PMID: 18254010] doi:10.1002 /14651858.CD002942.pub2.
Miglioretti DL, Lange J, van den Broek JJ, et al. (2016). Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening: A Modeling Study. Ann Intern Med 164 (4): 205-14, 2016. [PMC free article] [PubMed].
Hendrick RE. (2010). Radiation doses and cancer risks from breast imaging studies. Radiology. 2010;257:246-53. [PMID: 20736332] doi:10 .1148/radiol.10100570.
Yaffe MJ, Mainprize JG. (2011). Risk of radiation-induced breast cancer from mammographic screening. Radiology. 2011;258:98-105. [PMID: 21081671] doi:10.1148/radiol.10100655.
Pisano, E.D., et al. (2005). Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening. New England Journal of Medicine, 353 (17), 1773-1783.
Sechopoulos, I. (2013). A review of breast tomosynthesis. Medical Physics, 40(1) Scholar Publishing
Skaane, P., et al. (2013). Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology, 267(1), 47-56.
Vedantham, S., et al. (2015). Dedicated Cone-Beam Breast CT: Performance Evaluation of a Prototype Clinical System. Scientific Reports, 5, 12643.
Skaane, P., et al. (2013). Comparison of digital mammography alone and digital mammography plus tomosynthsies. Radiology.
Sechopoulos, I. (2013). A review of breast tomosynthesis. Part II. Medical Physics.
Friedewald, S. M., et al. (2014). Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA.
Zuckerman, S. P., et al. (2016). Implementation of synthesized two-dimensional mammography in a population-based screening program. Radiology.
Yun, G., Kim, S. M., Yun, B.L., Ahn, H.S., & Jang, M. (2019). Reliability of automated versus handheld breast ultrasound examinations of suspicious breast masses. Ultrasonography, 38(3), 264-
Iacob, R., Iacob, E.R., Stoicescu, E.R., et al. (2024). Evaluating the Role of Breast Cancer in Lowand Middle-Income Countries: A Comprehensive Narrative Review. Bioengineering, 11(3), 262.
Catalono, O., Fusco, R., De Muzio, F., et al. (2023). Recent Advances in Ultrasound Breast Imaging: From Industry to Clinical Practice. Diagnostics, 13(5), 980.
Brem, R.F., Lenihan, M.J., Lieberman, J., & Torrente, J. (2015). Screening Breast Ultrasound: Past, Present, and Future. American Journal of Roentgenology, 204(2), 234-240.
Kriege M, Brekelmans CT, Boetes C, et al. (2004). Efficacy of MRI and mammography for breastcancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351:427-437. Doi:10.1056/NEJMoa031759. [DOI] [PubMed][Google Scholar].
Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW. (2003). Mammography service screening and mortality in breast cancer patients: 20-years follow-up. Lancet. 2003; 361 (9363):1405-10.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. (2018). Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
Vercher-Conejero J.L., Pelegri-Martinez L., Lopez-Aznar D., Cozar-Santiago M.D.P. (2015). Positron Emission Tomography in Breast Cancer. Diagnostics. 2015;5:61-83. Doi:10.3390/diagnostics5010061. [DOI] [PMC free article] [Pubmed] [Google Scholar].
Chen CJ. Lee BF, Yao WJ, et al. (2009). A false positive F-FDG PET/CT scan caused by breast silicone injection. Korean J Radiol 2009; 10:194???196. [PubMed] [Google Scholar].
Yanai, A., Itoh, M., Hirakawa, H., Yanai, K. et al. (2018). Newly Developed Positron Emission Mammography (PEM) Device for the Detection of Small Breast Cancer. Tohoku J. Exp. Med: 245,13-19. [Google Scholar] [CrossRef].
Lee, K. (2011). Optical mammography: Diffuse optical imaging of breast cancer. World Journal of Clinical Oncology, 2(1), 64.
Poplack, S.P., Park, E-Y., & Ferrara, K.W. (2023). Optical Breast Imaging: A Review of Physical Principles, Technologies, and Clinical Applications. Journal of Breast Imaging, 5,520-537.
Kakileti, S.T; Manjunath, G; Madhu, H; Ramprakash, H.V. (2017). Advances in Breast Thermography. In New Perspectives in Breast Imaging, IntechOpen: London, UK; ISBN 978-953-51-3558-6. [Google Scholar].
Scholar Publishing Lee, K., et al. (2012). Thermography as a screening and diagnostic tool: a systematic review. The New Zealand Medical Journal.
Food and Drug Administration (FDA). (2019). Thermography Machines Are Not a Replacement for Mammograms: FDA Safety Communication.
Molina Healthcare. (2013). Thermography for the Detection of Breast Lesions (MCG-127). Clinical Policy Review.
UCHealth. (2022). Thermography is not FDA-approved as a screening tool for breast cancer. [interview with Dr. Olga Mengin, Harvard-trained breast radiologist].
Covington, M.F., Salmon, S., Weaver, B.D., & Fajardo, L, L. (2024). State-of-the-art for contrastenhanced mammography. Bristish Journal of Radiology, 97(1156), 695-704.
Moffa, G., Galati, F., Maroncelli, R., Rizzo, V., Cicciarelli, F., Pasculli, M., & Pediconi, F. (2023). Diagnostic performance of contrast-enhanced digital mammography versus conventional imaging in women with dense breasts. Diagnostics, 13(15), 2520.
Tari, (2025). Contrast-enhanced mammography in high-dense breasts: a narrative review. Translational Breast Cancer Research.
Barone, A. et al. (2024). ‘‘Evolution of Nuclear Medicine in Breast Cancer: From Scientimammography to Molecular Breast Imaging’’. Journal of Clinical Medicine, 13(4), 1102.
Jadvar, H. (2024). ‘‘Molecular Imaging of Breast Cancer: A Comprehensive Review’’. American Journal of Roentgenology, 222(2),145-158.
Nawaz, A. et al. (2023). ‘‘Diagnostic Accuracy of Scintimammography in the Evaluation of Breast Masses’’. Nuclear Medicine Communications, (44(8), 612-619.
BCBSM Medical Policy. (2026). Breast Elastography-Ultrasound or Magnetic Resonance. Blue Cross Blue Shield of Michigan. [Medical Policy Statement].
PMC (PubMed Central). (2026, March). Establishing an evidence-based modern breast MRI program. PMC12900033.
Slyyir Medical Journal. (2026). Differential diagnostic performance of acoustic radiation force implse imaging in small (≤20 mm) breast cancers.
Taylor & Francis. (2025, January). Computational predictions of magnetic resonance acoustic radiation force imaging for breast cancer.
Lee, S.H., Shin, H.J., & Moon, W. K. (2021). Diffusion-Weighted Magnetic Resonance Imaging of the breast: Standardization of image acquision and interpretation. Korean Journal of Radiology, 22(1),
Lo Gullo, R., Partidge, S. C., Shine, H.J., Takur, S.B., & Pinker, K. (2024). Update on DWI for breast cancer diagnosis and treatment monitoring. American Journal of Roentgenology, 222.
Mendez, A.M., Fang, L.K., Meriwether, C.H., Batasin, S.J.,Loubrie, S., Rodriguez-Soto, A.E., & Rakow-Penner, R.A. (2022). Diffusion breast MRI: Current standard and emerging techniques. Frontiers in Oncology, 12.
Partridge, S.C., & Amornsiripanitch, N. (2017). DWI in the assessment of breast lesions. Topics in Magnetic Resonance Imaging, 26(5), 201-209.
Bahl, M., Baker, J.A., Kinsey, E. N., & Ghate, S.V. (2015). Ductoscopy: A review of the literature and future directions. Journal of Breast Imaging, 1(1).
Scholar Publishing Hery, C., Ferlay, J., Boniol, M., & Autier, P. (2011). Quantification of the risk of breast cancer associated with ductal lavage findings: A meta-analysis. Breast Cancer Research and Treatment, 126(1),1-10.
Khan, S.A., Wiley, E.L., Rodringues, N., Baird, C., Ramakrishnan, R., Nayar, R.,… & Morrow, M. (2004). Ductal lavage findings in women with known breast cancer undergoing modified radical mastectomy. Cancer, 100(9), 1757-1763.
Moncrief, R.M., Nayar, R., Diaz, L.K., Staradub, V.L., Morrow, M., & Khan, S.A. (2005). A comparison of ductal lavage and nipple aspiration for the grade of cytology and immunoreactivity for p53, HER2/neu, and cyclin D1. Cancer, 103(9), 1773-1779.
Waaijer, L., Van Diest, P.J., Verkooijen, H.M., Koning, S.G., & Witkamp, A.J. (2016). The value of ductoscopy in patients with pathological nipple discharge: A systematic review. European Journal of Surgical Oncology (EJSO), 42(5), 629-642.
Li, X., et al. (2024). Radiomics analysis combining gray-scale ultrasound and mammography for differentiating breast adenosis from invasive ductal carcinoma. Frontiers in Oncology, 14.
PMC. (2026). Intergrating deep learning and radiomics for precise and radiomics for precise identification of luminal A/B breast cancer subtypes on dynamic contrast-enhanced MRI. PMC12958541.
Preprints.org. (2026). Potential of radiomics to improve diagnostic accuracy of mammograms and personalize patient management in breast cancer. Preprints 202601.0182.
Li, S., Qu, F., Yang, Y., Wang, L., Shen, J., & Shao, Z. (2020). Value of Stereotactic 11-gauge vacuum-assisted breast biopsy in non-palpable suspicious calcifications: An eight-year single institution experience with 587 patients. Gland Surgery, 9(5), 1258-1266.
Pyo, J.-S., Jung, J., Lee, S.G., Kim, N.-Y., &Kang, D.-W. (2020). Diagnostic accuracy of fine-needle aspiration cytology and core-needle biopsy in the assessment of the axillary lymph nodes in breast cancer – meta-analysis. Diagnostics, 10(9), 717.
Tikku, G., & Umap, P. (2015). Comparative study of core needle biopsy and fine needle aspiration cytology in palpable breast lumps: Scenario in developing nations. Turkisk Journal of Pathology.
AuntMinnieEurope. (2026). Photon-counting CT excels in cancer imaging. Clinical news report on recent oncology imaging advancements.
PMC (Pubmed Central). (2026). Photon-counting detector CT in oncology: a new era of cancer imaging. PMC12824093.
Joensuu H, Lehtimäki T, Holli K, et al. (2004). Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 292 (9): 1064-73, 2004. [PubMed].
Shen Y, Yang Y, Inoue LY, et al. (2005). Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 97 (16): 1195-203, 2005. [PubMed].
Wishart GC, Greenberg DC, Britton PD, et al. (2008). Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? Br J Cancer 98 (11): 1741-4, 2008. [PMC free article] [PubMed].
AJMC. (2026). Aligning the Stars: Quality Metrics Must Evolve From Screening Rate to Diagnostic Resolution. American Journal of Managed Care.
Frontiers in Public Health. (2025). Developing and validating key performance indicators for breast cancer screening programs: a literature review and Delphi survey. Frontiers. Scholar Publishing
Newell, M.S., et al. (2025). ACR BI-RADS. American College of Radiology. Reston, VA. Porter PL, El-
Bastawissi AY, Mandelson MT, et al. (2020). Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91 (23): 2020-8. [PubMed].
Niraula S, Biswanger N, Hu P, et al. (2020). Incidence, Characteristics, and Outcomes of Interval Breast Cancers Compared With Screening-Detected Breast Cancers. JAMA Netw Open 3 (9): e2018179, 2020. [PMC free article] [PubMed].
Sprague, B.L., Coley, R.Y., et al. (2023). Digital Tomosynthesis versus Digital Mammography Screening Performance on Successive Screening Rounds from the Breast Cancer Surveillance Consortium. Radiology, 307, e223142. [Doi] [PubMed] [Google Scholar].
PMC (2026). Beyond mammography Superior performance of ultrasound in early-onset breast cancer….
PMC (2026, Jan). Agreement Among Breast Cancer Screening Modalities in Breast Density Assessment and Cancer Risk Prediction. Journal of Clinical Medicine.
Annals of Internal Medicine (2026). Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Systematic Review for the U.S. Preventive Services Task Force.
UCLA Health (2026). Imaging Modalities: Specificity and Sensitivity Benchmarks in High-Risk Populations.
Grabler P. Sighoko D, Wang L, Allgood K, Ansell D. (2017). Recall and cancer detection rates for screening mammography: finding the sweet spot. AJR Am J Roentgenol; 208(1):208-213. Doi: 10.2214/AJR.15.15987. [PubMed] [Google Scholar].
Lowry, K.P.et al. (2020). Screening performance of digital breast tomosynthesis vs digital mammography in community practice by patient age, screening round, and breast density. JAMA New. Open3, e2011792 92020). [Doi] [PubMed] [Google Scholar].
Yoon, J.H. et al. (2023). Standalone AI for breast cancer detection at screening digital mammography and digital breast tomosynthesis: a systematic review and meta-analysis. Radiology307, e222639. [Doi] [PubMed] [Google Scholar].
Soren R. Christiansen, Philippe Autier, Henrik Stovering. (2022). European Journal of Public Health, World Health Organization (2026, April). Breast Cancer Fact Sheet.
ClinicaTrials.gov (2026). NCT05036096: Cone Beam Breast CT for Breast Cancer Screening. (Ongoing study focused on CBBCT efficacy; notably lacks a PCD-CT comparison arm).
Lachance, C.C., & Horton, J. (2024). ‘‘Photon-Counting CT: High Resolution, Less Radiation.’’ Canadian Journal of Health Technologies. (Discusses potential dose benefits over conventional CT/CBCT but identifies the lack of large-scale comparative RCTs as a primary limitation).
Pace, L.E., & Keating, N.L. (2014). A Systematic Assessment of the Benefits and Risks to Guide Breast Cancer Screening Decisions. JAMA.
Marmot, M.G., et al. (2013). The benefits and harms of breast cancer screening: an independent review. British Journal of Cancer.
Journal of Clinical Oncology (2026): Genomic assay utility in Node-Positive (N1) Disease. Discusses the reduction of chemotherapy in postmenpausal Stage 2 patients. https://www.verywellhealth.com/stages-of-breast-cancer-8362458).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ugochukwu maluze
This work is licensed under a Creative Commons Attribution 4.0 International License.
